Anthera Pharmaceuticals Gets a Hold Rating from Jefferies

By Austin Angelo

In a report released today, Matthew Andrews from Jefferies reiterated a Hold rating on Anthera Pharmaceuticals (NASDAQ: ANTH), with a price target of $2.25. The company’s shares opened today at $2.12, close to its 52-week low of $0.33.

According to TipRanks.com, Andrews is a 2-star analyst with an average return of 0.0% and a 41.5% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Spectrum Pharmaceuticals, and CytomX Therapeutics Inc.

Anthera Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $1.63.

The company has a one year high of $32.00 and a one year low of $0.33. Currently, Anthera Pharmaceuticals has an average volume of 2.7M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase. Anthera Pharmaceuticals was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.